Quarterly ResultMay 14, 2026, 06:32 AM
Fennec Q1 Revenue $15.1M, Up 73%; Achieves Net Income $0.2M
AI Summary
Fennec Pharmaceuticals reported strong first-quarter 2026 financial results, with total net revenues increasing 73% year-over-year to $15.1 million and achieving a net income of $0.2 million, compared to a net loss in the prior year. The company highlighted continued growth in PEDMARK® adoption, positive early results from its field sales expansion, and the initiation of a third institution-led clinical study for PEDMARK®. Additionally, four abstracts evaluating PEDMARK® will be presented at the 2026 ASCO Annual Meeting.
Key Highlights
- Q1 2026 net revenues grew 73% YoY to $15.1 million.
- Achieved Q1 2026 net income of $0.2 million, up from a $1.2 million net loss.
- Basic EPS was $0.01 in Q1 2026, compared to $(0.04) in Q1 2025.
- Cash and cash equivalents increased to $40.1 million as of March 31, 2026.
- Initiated third clinical study for PEDMARK® in AYA and adult head/neck/testicular cancers.
- Four PEDMARK® abstracts accepted for the 2026 ASCO Annual Meeting program.
- Selling and marketing expenses rose to $11.4 million from $3.2 million YoY.